Literature DB >> 19247084

Tumorlets, multicentric carcinoids, lymph-nodal metastases, and long-term behavior in bronchial carcinoids.

Piero Ferolla1, Niccolò Daddi, Moira Urbani, Antonia Semeraro, Rodolfo Ribacchi, Paolo Giovenali, Stefano Ascani, Verena De Angelis, Lucio Crinò, Francesco Puma, Giuliano Daddi.   

Abstract

BACKGROUND: The clinical significance of lymph-node metastases, multicentric forms, and tumorlets in bronchial carcinoids is still a matter of debate. Aim of this study was to analyze their prevalence and clinical significance in a series of 123 bronchial carcinoids. PATIENTS AND METHODS: Nodal dissection and serial sections of resected lung parenchima for research of multicentric forms and tumorlets were performed in most patients. Survival curve was produced using the Kaplan-Meyer method and multivariate analysis by the Cox proportional hazard model.
RESULTS: Lymph-node involvement was present in 14% of typical (14 of 100) and 13.04% of atypical carcinoids (3 of 23). Multicentric forms (syncronous carcinoids or tumorlets) were found in 11.3% of the total with a negative impact on survival (p = 0.021). Multiple tumorlets were found in 7.3% of all cases at the standard pathologic examination, but whenever accurate palpation and serial sections of the surgical specimen were performed, the percentage reached 24% of the cases. Overall survival was 98.2%, 95.8%, and 83.9% for typical and 71.6%, 57.3%, and 24% for atypical carcinoid respectively at 5, 10, and 15 years. Time from surgery was significantly directly correlated with recurrences (p < 0.0001) and disease related death (p = 0.0002).
CONCLUSIONS: A high prevalence of tumorlets, multiple carcinoids, and lymph-nodal involvement was found in our series. On the basis of these observations bronchial carcinoids always require major surgical procedures with systematic nodal dissection, and a careful search for multifocal lesions should always be performed. Follow-up should always be accurate and protracted, due to the frequency of very long-term relapses (often more than 10 years after surgery).

Entities:  

Mesh:

Year:  2009        PMID: 19247084     DOI: 10.1097/JTO.0b013e318197f2e7

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  13 in total

Review 1.  Lung neuroendocrine tumors: pathological characteristics.

Authors:  Luisella Righi; Gaia Gatti; Marco Volante; Mauro Papotti
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

Review 2.  Cardiothoracic manifestations of neuroendocrine tumours.

Authors:  Ramin Mandegaran; Sarojini David; Nicholas Screaton
Journal:  Br J Radiol       Date:  2016-01-19       Impact factor: 3.039

3.  Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study.

Authors:  A Faggiano; P Ferolla; F Grimaldi; D Campana; M Manzoni; M V Davì; A Bianchi; R Valcavi; E Papini; D Giuffrida; D Ferone; G Fanciulli; G Arnaldi; G M Franchi; G Francia; G Fasola; L Crinò; A Pontecorvi; P Tomassetti; A Colao
Journal:  J Endocrinol Invest       Date:  2011-11-09       Impact factor: 4.256

Review 4.  Classification of lung neuroendocrine tumors: lights and shadows.

Authors:  Marco Volante; Gaia Gatti; Mauro Papotti
Journal:  Endocrine       Date:  2015-03-21       Impact factor: 3.633

Review 5.  Management of pulmonary neuroendocrine tumors.

Authors:  Robert A Ramirez; Aman Chauhan; Juan Gimenez; Katharine E H Thomas; Ioni Kokodis; Brianne A Voros
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

6.  Endobronchial Carcinoids: Surgical Outcome in 100 Consecutive Patients and Factors Affecting Lung Preservation.

Authors:  Sukhram Bishnoi; Belal Bin Asaf; Harsh Vardhan Puri; Mohan Venkatesh Pulle; Srinivas Kodaganur Gopinath; Shikha Sharma; Mitul Vinodbhai Patel; Arvind Kumar
Journal:  Indian J Surg Oncol       Date:  2020-10-21

7.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs).

Authors:  John K Ramage; A Ahmed; J Ardill; N Bax; D J Breen; M E Caplin; P Corrie; J Davar; A H Davies; V Lewington; T Meyer; J Newell-Price; G Poston; N Reed; A Rockall; W Steward; R V Thakker; C Toubanakis; J Valle; C Verbeke; A B Grossman
Journal:  Gut       Date:  2011-11-03       Impact factor: 23.059

8.  Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms.

Authors:  Daniel Kaemmerer; Christiane Reimann; Elisa Specht; Ralph M Wirtz; Manal Sayeg; Richard P Baum; Stefan Schulz; Amelie Lupp
Journal:  Oncotarget       Date:  2015-02-20

9.  Surgical management of bronchopulmonary carcinoids: A single center experience.

Authors:  Ashish Jakhetiya; Pankaj Kumar Garg; Rambha Pandey; Palaniappan Ramanathan; Sunil Kumar; Debojit Nath; Durgatosh Pandey
Journal:  South Asian J Cancer       Date:  2017 Jan-Mar

10.  Somatostatin receptor PET/CT in restaging of typical and atypical lung carcinoids.

Authors:  Vikas Prasad; Ingo G Steffen; Marianne Pavel; Timm Denecke; Elisabeth Tischer; Konstantina Apostolopoulou; Andreas Pascher; Ruza Arsenic; Winfried Brenner
Journal:  EJNMMI Res       Date:  2015-10-12       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.